| __timestamp | Arrowhead Pharmaceuticals, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 1860000 |
| Thursday, January 1, 2015 | 34718089 | 2963000 |
| Friday, January 1, 2016 | 40998209 | 6961000 |
| Sunday, January 1, 2017 | 32022880 | 11779000 |
| Monday, January 1, 2018 | 19110051 | 13697000 |
| Tuesday, January 1, 2019 | 26556257 | 15749000 |
| Wednesday, January 1, 2020 | 52275890 | 18638000 |
| Friday, January 1, 2021 | 80981000 | 27196000 |
| Saturday, January 1, 2022 | 124431000 | 31739000 |
| Sunday, January 1, 2023 | 90932000 | 33491000 |
| Monday, January 1, 2024 | 98761000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining financial health. Arrowhead Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, Arrowhead's SG&A expenses surged by approximately 300%, peaking in 2022. This increase reflects their aggressive expansion and investment in administrative capabilities. In contrast, Protagonist Therapeutics maintained a more conservative growth, with SG&A costs rising by about 170% over the same period. Notably, Protagonist's expenses remained consistently lower, suggesting a more controlled cost management strategy. However, data for 2024 is missing for Protagonist, leaving room for speculation on their future trajectory. As these companies navigate the biotech landscape, their differing strategies in managing SG&A costs offer valuable insights into their operational priorities and financial strategies.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: AbbVie Inc. vs Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Viatris Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
ADMA Biologics, Inc. vs Arrowhead Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Apellis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Geron Corporation
Comparing SG&A Expenses: Protagonist Therapeutics, Inc. vs MannKind Corporation Trends and Insights